| 摘要 |
PURPOSE:To obtain an anti-inflammatory agent having stability of an active ingredient higher than that of a conventional anti-inflammatory agent blended with astaxanthin, being expected to have higher effect, capable of lightening adverse effect of other anti-inflammatory agents and medicine components. CONSTITUTION:An anti-inflammatory agent comprises a diester of astaxanthin, preferably a fatty acid diester or a glycerophosphoric acid diester of astaxanthin. The diesters are extracted from a krill. When the diesters are identified by using a high-performance liquid chromatography, a column of RPC Microbondapach NH2 made of Waters Inc. (deltamm. i. dX-10mm) is used and n-hexane:2-propanolmethanol=75:15 is used for a mobile phase. In the case of making the diester flow at 2m/minute flow rate and observing absorption at 470nm by an ultraviolet light and visible light absorption spectrum detector, the diesters having a retention time providing the maximum peak in the range of 0.5-2.5 minute are preferable. When the diesters are blended with an aspirin preparation, adverse effects are lightened and an aspirin acid agent having increased effect can be obtained. |
